ConductScience.org, home

Paper25614146

Camelid nanobodies: killing two birds with one stone.

Desmyter A and 3 others. Curr Opin Struct Biol, 2015. Cited by 91 papers, by iCite.

Cite this record

ConductScience Library. Camelid nanobodies: killing two birds with one stone. Papers, record 25614146. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/25614146

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Camelid nanobodies: killing two birds with one stone.
PubMed
Journal
Curr Opin Struct Biol
PubMed
Year
2015
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
91
iCite
Relative citation ratio, by iCite
3.07
iCite
Revised in PubMed
2015-07-22
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Desmyter AAline
2Spinelli SSilvia
3Roussel AAlain
4Cambillau CChristian

Source PubMed

Download CSV of authors

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Camelids, New WorldMajor topic
ProteinsMajor topic
Single-Domain AntibodiesMajor topic
Animals
Crystallization
Humans
Models, Molecular
Protein Conformation
Protein Stability

Source PubMed

Download CSV of topics

Cited by64

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 91 citations.

PMIDTitleJournalYearIn PapersSource
42352241Ocular Safety of Intravitreal Engineered Humanized Anti-VEGF Nanobody and Its Efficacy in the Attenuation of Choroidal Neovascularization and Associated Subretinal Fibrosis.Biomolecules2026https://conductscience.org/library/papers/42352241PubMed
42121126Affinity enhancement of an anti-VEGF humanized nanobody as a superior candidate to bevacizumab: integrative in silico and in vitro studies.BMC Biotechnol2026https://conductscience.org/library/papers/42121126PubMed
41953754Generation of Nano-Antibodies Targeting the SNMP1 Membrane Receptor of Spodoptera littoralis Using Extracellular Vesicles.J Extracell Biol2026https://conductscience.org/library/papers/41953754PubMed
41704535VNAR: shark single-domain antibodies for the new era of medical biotechnology.Front Immunol2025https://conductscience.org/library/papers/41704535PubMed
41324409Single mutations to tyrosine or glutamate improve the crystallizability and crystal diffraction properties of a flexible two-domain protein.Acta Crystallogr F Struct Biol Commun2026https://conductscience.org/library/papers/41324409PubMed
41141363Optimization of the VSV-G backbone for amino terminal fusion with nanobodies allowing its specific retargeting to HER2 receptors.Mol Ther Oncol2025https://conductscience.org/library/papers/41141363PubMed
40634277Targeting CD155 in lung adenocarcinoma: A5 nanobody-based therapeutics for precision treatment and enhanced drug delivery.Signal Transduct Target Ther2025https://conductscience.org/library/papers/40634277PubMed
40474190A phage-displayed nanobody-based competitive immunoassay for the detection of African swine fever virus antibodies.Virol J2025https://conductscience.org/library/papers/40474190PubMed
40427736Nanobodies: From Discovery to AI-Driven Design.Biology (Basel)2025https://conductscience.org/library/papers/40427736PubMed
40410172Emerging biosensors integrated with microfluidic devices: a promising analytical tool for on-site detection of mycotoxins.NPJ Sci Food2025https://conductscience.org/library/papers/40410172PubMed
40275270Advancing pancreatic cancer therapy by mesothelin-specific nanobody conjugation.Mol Cancer2025https://conductscience.org/library/papers/40275270PubMed
38771414Nanobodies in the fight against infectious diseases: repurposing nature's tiny weapons.World J Microbiol Biotechnol2024https://conductscience.org/library/papers/38771414PubMed
38687705An optimized approach to study nanoscale sarcomere structure utilizing super-resolution microscopy with nanobodies.PLoS One2024https://conductscience.org/library/papers/38687705PubMed
38512665Recombinant Production and Characterization of VHHs/Nanobodies Targeting Tau to Block Fibrillar Assembly.Methods Mol Biol2024https://conductscience.org/library/papers/38512665PubMed
38350843Single-domain antibodies against SARS-CoV-2 RBD from a two-stage phage screening of universal and focused synthetic libraries.BMC Infect Dis2024https://conductscience.org/library/papers/38350843PubMed
38341572Development and characterization of a novel nanobody with SRMV neutralizing activity.Microb Cell Fact2024https://conductscience.org/library/papers/38341572PubMed
37533864A comparison of the binding sites of antibodies and single-domain antibodies.Front Immunol2023https://conductscience.org/library/papers/37533864PubMed
37328468Structure and antigenicity of divergent Henipavirus fusion glycoproteins.Nat Commun2023https://conductscience.org/library/papers/37328468PubMed
35646824Deciphering the Structure and Formation of Amyloids in Neurodegenerative Diseases With Chemical Biology Tools.Front Chem2022https://conductscience.org/library/papers/35646824PubMed
35157279Humanization of Camelid Single-Domain Antibodies.Methods Mol Biol2022https://conductscience.org/library/papers/35157279PubMed

See all 64 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/25614146

GET https://conductscience.org/api/papers/v1/25614146/cited_by?page=2